Results 61 to 70 of about 1,721,954 (363)

Challenges in constructing genetic instruments for pharmacologic therapies [PDF]

arXiv, 2020
The genes that encode the targets of most therapies do not have rare variants with large-effect or common variants with moderate effects on the biomarker reflecting the pharmacologic action of the corresponding therapy. Therefore, providing genetic target validation for most therapies is challenging.
arxiv  

Sculpting the tumour microenvironment by combining radiotherapy and ATR inhibition for curative-intent adjuvant immunotherapy

Nature Communications
The combination of radiotherapy/chemoradiotherapy and immune checkpoint blockade can result in poor outcomes in patients with locally advanced head and neck squamous cell carcinoma (HNSCC).
Emmanuel C. Patin, Pablo Nenclares, Charleen Chan Wah Hak, Magnus T. Dillon, Anton Patrikeev, Martin McLaughlin, Lorna Grove, Shane Foo, Heba Soliman, Joao P. Barata, Joanna Marsden, Holly Baldock, Jim Gkantalis, Victoria Roulstone, Joan Kyula, Amy Burley, Lisa Hubbard, Malin Pedersen, Simon A. Smith, Eleanor Clancy-Thompson, Alan A. Melcher, Masahiro Ono, Antonio Rullan, Kevin J. Harrington   +23 more
doaj   +1 more source

A Highlight of the Mechanisms of Immune Checkpoint Blocker Resistance

Frontiers in Cell and Developmental Biology, 2020
In recent years, as our understanding of tumor immunology is continuously improved, immunotherapy has come to the center stage of cancer therapy and is deemed as the most promising approach for cancer control.
Qian Huang, Yanna Lei, Xiaoying Li, Fukun Guo, Ming Liu   +4 more
doaj   +1 more source

FoxO1 signaling in B cell malignancies and its therapeutic targeting

FEBS Letters, EarlyView.
FoxO1 has context‐specific tumor suppressor or oncogenic character in myeloid and B cell malignancies. This includes tumor‐promoting properties such as stemness maintenance and DNA damage tolerance in acute leukemias, or regulation of cell proliferation and survival, or migration in mature B cell malignancies.
Krystof Hlavac, Petra Pavelkova, Laura Ondrisova, Marek Mraz   +3 more
wiley   +1 more source

Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. [PDF]

, 2019
Optimization of post-remission therapies to maintain complete remission and prevent relapse is a major challenge in treating patients with acute myeloid leukemia (AML).
Chan, Steven M, Daver, Naval G, Jonas, Brian A, Medeiros, Bruno C, Pollyea, Daniel A   +4 more
core   +1 more source

Palliative Gastrectomy vs. Gastrojejunostomy for Advanced Gastric Cancer: A Systematic Review and Meta-Analysis

Frontiers in Surgery, 2021
Background: Advanced gastric cancer is the fifth leading cause of cancer-related deaths. Patients with metastatic advanced gastric cancer commonly develop a gastric outlet obstruction that considerably worsens their quality of life.
Chunfang Lin, Haibo Fan, Wenjun Chen, Lingzhi Cui   +3 more
doaj   +1 more source

The immunological interface: dendritic cells as key regulators in metabolic dysfunction‐associated steatotic liver disease

FEBS Letters, EarlyView.
Metabolic dysfunction‐associated steatotic liver disease (MASLD) affects nearly one‐third of the global population and poses a significant risk of progression to cirrhosis or liver cancer. Here, we discuss the roles of hepatic dendritic cell subtypes in MASLD, highlighting their distinct contributions to disease initiation and progression, and their ...
Camilla Klaimi, WanTing Kong, Camille Blériot, Joel T. Haas   +3 more
wiley   +1 more source

Melanocortin 1 receptor targeted imaging of melanoma with gold nanocages and positron emission tomography [PDF]

, 2018
Purpose: Melanoma is a lethal skin cancer with unmet clinical needs for targeted imaging and therapy. Nanoscale materials conjugated with targeting components have shown great potential to improve tumor delivery efficiency while minimizing undesirable ...
Black, Kvar, Detering, Lisa, Liu, Yongjian, Luehmann, Hannah, Pang, Bo, Sultan, Deborah, Xia, Younan, Yang, Miaoxin, Zhao, Yongfeng   +8 more
core   +2 more sources

Tenascin-C Downregulates Wnt Inhibitor Dickkopf-1, Promoting Tumorigenesis in a Neuroendocrine Tumor Model

Cell Reports, 2013
The extracellular matrix molecule tenascin-C (TNC) is a major component of the cancer-specific matrix, and high TNC expression is linked to poor prognosis in several cancers.
Falk Saupe, Anja Schwenzer, Yundan Jia, Isabelle Gasser, Caroline Spenlé, Benoit Langlois, Martial Kammerer, Olivier Lefebvre, Ruslan Hlushchuk, Tristan Rupp, Marija Marko, Michael van der Heyden, Gérard Cremel, Christiane Arnold, Annick Klein, Patricia Simon-Assmann, Valentin Djonov, Agnès Neuville-Méchine, Irene Esposito, Julia Slotta-Huspenina, Klaus-Peter Janssen, Olivier de Wever, Gerhard Christofori, Thomas Hussenet, Gertraud Orend   +24 more
doaj   +1 more source

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

Frontiers in Oncology, 2022
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders ...
Yaxun Jia, Min Wang, Xiaolin Sang, Pixu Liu, Jingchun Gao, Kui Jiang, Hailing Cheng   +6 more
doaj   +1 more source